Eisai launches LEQEMBI in India for early Alzheimer’s disease treatment
Launch follows CDSCO marketing authorisation for disease-modifying therapy indicated for patients with mild cognitive impairment…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
lecanemab
Eisai completes rolling submission to US FDA for LEQEMBI IQLIK supplemental biologics license…
Eisai announced that it has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the US…
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab…
Australia’s Alzheimer’s patients await potential treatment shift as TGA reviews Lilly’s donanemab following lecanemab rejection
Alzheimer’s drug Leqembi launched by Eisai, Biogen in China
China is the third country to launch LEQEMBI following the US and Japan
Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease
Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway
Eisai files for approval of Alzheimer’s drug in Japan
The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…
Eisai files for approval of Alzheimer’s drug in Europe
The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called…